Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | NPC1 | O15118 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | MITF | O75030 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.56 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2096261 | 0.88 | TP53 (0.68) | TP53TSHRRXFP1POLBRAB9A | |
| SCHEMBL2098029 | 0.84 | CA2 (0.54) | TP53TSHRRXFP1RAB9ANPC1 | |
| SCHEMBL6474439 | 0.83 | TP53 (0.66) | TP53TSHRRXFP1POLBRAB9A | |
| SCHEMBL2089860 | 0.83 | LMNA (0.47) | TP53TSHRRXFP1POLBRAB9A | |
| SCHEMBL4893387 | 0.82 | TP53 (0.87) | TP53TSHRRXFP1RAB9ANPC1 | |
| SCHEMBL31040569 | 0.82 | TP53 (0.87) | TP53TSHRRXFP1RAB9ANPC1 | |
| SCHEMBL3983838 | 0.82 | ALDH1A1 (0.73) | TP53TSHRRXFP1POLBRAB9A | |
| SCHEMBL2095225 | 0.81 | TP53 (0.68) | TP53TSHRRXFP1POLBRAB9A | |
| SCHEMBL31728556 | 0.81 | RAB9A (0.71) | TP53TSHRRXFP1POLBRAB9A | |
| SCHEMBL2095227 | 0.81 | RAB9A (0.71) | TP53TSHRRXFP1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7081481-B2 | Excitatory amino acid receptor modulators | ELI LILLY AND COMPANY (US) | 2006-07-25 | — | — | US | claimed |
| US-20040102521-A1 | Excitatory amino acid receptor modulators | ELI LILLY AND COMPANY | 2004-05-27 | — | — | US | claimed |
| EP-1289940-A2 | EXCITATORY AMINO ACID RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-03-12 | — | — | EP | claimed |
| WO-2001092213-A2 | EXCITATORY AMINO ACID RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2001-12-06 | — | — | WO | claimed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-7081481-B2 | Excitatory amino acid receptor modulators | ELI LILLY AND COMPANY (US) | 2006-07-25 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| US-20040102521-A1 | Excitatory amino acid receptor modulators | ELI LILLY AND COMPANY | 2004-05-27 | — | — | US | disclosed |
| EP-1289940-A2 | EXCITATORY AMINO ACID RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001092213-A2 | EXCITATORY AMINO ACID RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102521-A1 | Excitatory amino acid receptor modulators | GRM1, GRM2, GRIN1 | TP53 4884/4885TSHR 443/4885RXFP1 355/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | TP53 4732/4885TSHR 162/4885RXFP1 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.